Nezam H. Afdhal is Chief Medical Officer at Spring Bank Pharmaceuticals, Inc. (SBPH). They have made 5 open-market trades across 1 company since 2016, most recently 2016-11-23.
CIK 0001566373
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $162K since 2016, never a sale. Across 5 scored buys the stock is down 27.4% at ninety days, and 28.3 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| SBPH | 53,300 | $258K |
Shares reported on the most recent Form 4, priced at the 2016-11-23 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 80% | 80% | 0% |
| Avg Move | +8.1% | +9.7% | -27.4% |
| Alpha | +7.9% | +10.9% | -28.3% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SBPH | BUY | 2016-09-09 | 2016-09-12 | $12.50 | $30K | -3.7% | -3.9% | -36.9% |
| SBPH | BUY | 2016-08-24 | 2016-08-24 | $11.92 | $24K | +6.0% | +5.8% | -26.3% |
| SBPH | BUY | 2016-08-15 | 2016-08-16 | $11.43 | $22K | +13.4% | +17.1% | -23.5% |
| SBPH | BUY | 2016-08-12 | 2016-08-15 | $11.33 | $29K | +11.3% | +12.2% | -26.5% |
| SBPH | BUY | 2016-08-10 | 2016-08-16 | $11.01 | $57K | +13.4% | +17.1% | -23.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.